Abstract:Despite several advances in percutaneous coronary intervention and the discovery of new drugs, the incidence of myocardial infarction and deaths due to cardiovascular diseases (CVD) has not decreased markedly in China. The quality of life is affected seriously, which further results in great social and family burden. Many drugs, from the century-old aspirin to the newly FDA-approved Byvalson, have been proven to be effective in the treatment and prevention of CVD. As clinically reported, those life-saving drugs still have their side effects in regards to the narrow therapeutic indexes influenced by individual genetic variations. Herba Leonuri, also known as Chinese Motherwort, which are naturally present in plants and traditionally are used for the uterotonic action, postpartum blood stasis, breast pain as well as other gynecological disorders in China for thousands of years. Since the last two decades, our group has reported leonurine, a unique alkaloid found in Herba Leonuri, exhibits various bioactivities such as antioxidant, anti-apoptotic effects, free radical scavenging and anti-inflammatory effects, in addition to improving micro-circulation. These bioactivities are related to the underlying mechanisms of ischemic heart diseases and cardiac fibrosis. Pharmacological studies have proven leonurine to be effective in treating CVD in various ways, particularly ischemic heart diseases. Besides the cardio protective effects, which are similar in the central nervous system, more specifically, inhibited mitochondrial reactive oxygen species production together with the restored mitochondrial function and redox state were observed in middle cerebral artery occlusion rats by leonurine treatment, which strongly reveals its neuroprotective effects and carries a therapeutic potential for recovery and prevention of stroke. Based on their mode of action, we propose that leonurine can be developed as drugs to treat ischemic heart diseases. Taking advantage of the most recent findings in pharmacological research including the effects of low toxicity and good pharmacokinetics characteristics, leonurine has a very attractive prospect of clinical application. Our recent promising pharmacological results may be able to eradicate the barrier hindering its sale on market. In sum, from bench to bedside is no longer a long way for leonurine.

Improved synthesis of leonurine as cardioprotective agent

Improved Synthetic Process for 3-Benzyloxy-4-n-butylaniline Hydrochloride

Synthesis of 5-Hydroxylevulinic Acid from Levulinic Acid

Synthesis technology of 3-n-propyl-2, 4-dihydroxyacetophenone

3,5-Dimethoxy-4-(3-(2-carbonyl-ethyldisulfanyl)-propionyl)-benzoic acid 4-guanidino-butyl ester: A novel twin drug that prevents primary cardiac myocytes from hypoxia-induced apoptosis

ChemInform Abstract: Synthesis and Biological Evaluation of Novel Leonurine-SPRC Conjugate As Cardioprotective Agents.

ChemInform Abstract: An Improved Synthesis of a β‐Blocker Celiprolol Hydrochloride (X).

Synthesis and Biological Evaluation of the Codrug of Leonurine and Aspirin As Cardioprotective Agents

An Improved Synthesis Of A Beta-Blocker Celiprolol Hydrochloride

A Concise Synthesis of 2-Chloro-3-amino-4-methylpyridine

Discovery of Leonuri and therapeutical applications: From bench to bedside

Leonurine-cysteine Analog Conjugates As a New Class of Multifunctional Anti-Myocardial Ischemia Agent.

Natural products in drug discovery and development: Synthesis and medicinal perspective of leonurine

Quantification of leonurine, a novel potential cardiovascular agent, in rat plasma by liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic study in rats.

4-Guanidino-n-butyl Syringate (leonurine, SCM 198) Protects H9c2 Rat Ventricular Cells from Hypoxia-induced Apoptosis

Leonurine: a comprehensive review of pharmacokinetics, pharmacodynamics, and toxicology

Protective effects of leonurine in neonatal rat hypoxic cardiomyocytes and rat infarcted heart.

The Synthetic Technology of Ranolazine

Leonurine (SCM-198) improves cardiac recovery in rat during chronic infarction.

Effect of Leonurine on Blood Lipid in Experimental Hyperlipidemia Rats

Characterization of Metabolites of Leonurine (SCM-198) in Rats after Oral Administration by Liquid Chromatography/tandem Mass Spectrometry and NMR Spectrometry.